Zhang JT, Li Y, Yan LX, et al. - In this multi-center retrospective study, data from 381 individuals with pulmonary large-cell neuroendocrine carcinoma (LCNEC) admitted to 17 Chinese institutes between 2009 and 2016 were retrospectively obtained and clinical features and prognosis were assessed among individuals receiving adjuvant (n = 56) and first-line (n = 146) chemotherapy, and those receiving small cell lung cancer (SCLC) and non-SCLC (NSCLC) chemotherapy regimens in order to contrast the clinical outcomes of pure vs combined LCNEC. When contrasted to the NSCLC regimen for LCNEC treatment, the SCLC regimen was discovered to be a more efficient option, as either first-line or adjuvant chemotherapy.